Retatrutide: The Next-Generation Triple Agonist Advancing Obesity and Metabolic Treatment

By Mohsen Halaby, MD

Board-Certified in Internal Medicine

Founder, Carebridge Medical

Serving Patients in Ohio & California

In recent years, GLP-1 receptor agonists have transformed the treatment landscape for obesity and type 2 diabetes. Now, Eli Lilly’s investigational agent retatrutide is generating significant interest as a potential next step in metabolic therapy.

Although still awaiting FDA approval, retatrutide introduces a novel triple-agonist approach that may further advance outcomes for patients with complex metabolic disease.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational, once-weekly injectable medication developed by Eli Lilly. It functions as a triple agonist, simultaneously activating three hormone receptors:

• GLP-1 (glucagon-like peptide-1)

• GIP (glucose-dependent insulinotropic polypeptide)

• Glucagon receptor

This distinguishes it from currently approved therapies that target one pathway (GLP-1 alone, such as semaglutide) or two pathways (GLP-1 + GIP, such as tirzepatide).

Why Target Three Hormonal Pathways?

Obesity is increasingly recognized as a hormonally mediated, chronic metabolic disease rather than a simple lifestyle condition.

Each receptor plays a unique role:

GLP-1 activation

• Enhances glucose-dependent insulin secretion

• Reduces appetite

• Slows gastric emptying

GIP activation

• Augments insulin response

• May influence fat metabolism and adipose signaling

Glucagon receptor activation

• Increases energy expenditure

• Promotes lipolysis (fat breakdown)

The triple-agonist model aims to combine appetite suppression with increased metabolic rate and fat oxidation — potentially addressing limitations observed in single- or dual-pathway therapies.

Clinical Trial Highlights

In earlier phase 2 trials, retatrutide demonstrated substantial weight reductions — up to approximately 24% at 48 weeks in adults with obesity without diabetes — along with improvements in cardiometabolic markers.

In December 2025, Eli Lilly announced positive topline results from the TRIUMPH-4 phase 3 trial (adults with obesity or overweight and knee osteoarthritis, without diabetes). At 68 weeks:

• Up to 28.7% average body weight reduction (~71.2 lbs) on the 12 mg dose

• 26.4% average reduction on the 9 mg dose

• Up to 75.8% reduction in knee pain (WOMAC scale)

• More than 1 in 8 participants reported complete resolution of knee pain

The broader TRIUMPH program includes multiple phase 3 studies evaluating obesity, type 2 diabetes, cardiovascular outcomes, sleep apnea, and other metabolic complications, with additional data anticipated throughout 2026.

Important: Retatrutide remains investigational and is not FDA-approved. Long-term safety, cardiovascular event reduction, and durability of effect are still under evaluation.

Side Effect Profile

As with other incretin-based therapies, gastrointestinal effects are the most commonly reported:

• Nausea

• Vomiting

• Diarrhea

• Abdominal discomfort

Gradual dose escalation improves tolerability.

In TRIUMPH-4, discontinuation rates due to adverse events were higher in active treatment groups (12–18%) compared to placebo (~4%), primarily due to gastrointestinal effects or concerns about excessive weight loss. A dose-related signal for dysesthesia (abnormal skin sensations) was also observed.

Comprehensive long-term safety data remains pending.

Current Availability

Retatrutide is not commercially available and is restricted to clinical trials.

Patients should avoid unregulated “research peptide” or compounded versions marketed online. These products lack FDA oversight, pose safety risks, and cannot be legally compounded under current federal law.

Broader Implications for Metabolic Medicine

Retatrutide reflects a broader paradigm shift in obesity care: treating metabolic disease as a chronic, hormonally driven condition requiring targeted pharmacologic intervention.

If supported by full phase 3 data, triple-agonist strategies may enhance:

• Metabolic flexibility

• Sustained fat oxidation

• Appetite regulation

• Cardiometabolic risk reduction

Retatrutide may ultimately represent one of the most potent pharmacologic options in the obesity treatment pipeline — pending regulatory approval.

Carebridge Medical’s Perspective

At Carebridge Medical, we closely monitor emerging therapies while maintaining a commitment to evidence-based care.

For patients exploring weight management, we:

• Perform comprehensive metabolic assessments

• Discuss FDA-approved treatment options

• Monitor laboratory and clinical response

• Develop individualized, physician-guided plans

New therapies will be incorporated only when supported by robust long-term data and regulatory approval.

Final Perspective

Retatrutide holds significant promise as the next evolution in metabolic therapy. However, enthusiasm must be balanced with scientific rigor and regulatory oversight.

Treatment decisions should always be based on approved evidence and personalized medical evaluation.

If you are interested in current, FDA-approved weight management strategies or optimizing your metabolic health, Carebridge Medical offers physician-led virtual consultations in Ohio, with expansion to California underway.

Reach out to learn more.